Arc-02

Phase 1

Taiho Oncology, Inc.

Arc-02 is one of 8 therapeutic programs targeting B-cell Non Hodgkin Lymphoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

B-Cell Non Hodgkin LymphomaRecruiting

B-Cell Non Hodgkin LymphomaPhase 1

Recruiting

Competition

Competitive Landscape

10 competitors in B-Cell Non Hodgkin Lymphoma

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

1 2

Tazverik

EEpizyme, Inc.

Phase 2

1 3

Surovatamig

AstraZeneca

Phase 2

1 4

Rituxan

Roche

Phase 1

1 5

Calquence

AstraZeneca

Preclinical

1 6

Yescarta

Gilead

Preclinical

1 7

Arc-02

Taiho Oncology, Inc.

Phase 1

1 8

AZD4512

AstraZeneca

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 1Recruiting

B-Cell Non Hodgkin Lymphoma

NCT07691606

Clinical

Trials by Indication[1]

B-cell Non Hodgkin Lymphoma1 trial

A Study to Evaluate Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity of ARC-02 in Adult Participants With B-cell Non-Hodgkins Lymphoma (NHL)

Recruiting· Taiho Oncology, Inc. logo

Taiho Oncology, Inc.·Phase 1·NCT07691606·140 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Arc-02. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Arc-02. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Taiho Oncology, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: Taiho Oncology, Inc.

Arc-02

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

B-cell Non Hodgkin Lymphoma1 trial

References

Drug Info

Quick Facts

Related News